The Journal of Organic Chemistry
Article
tert-Butyl (S)-2-Methyl-3-oxo-4,5-dipropyl-3,6-dihydropyridine-
1(2H)-carboxylate (3ac). The general procedure G1 was used with
63.2 mg (0.34 mmol, 0.2 M) of enantiopure 2-methyl-3-azetidinone
2c, 56.4 mg (0.51 mmol) of 4-octyne 1a, 11.2 mg (0.02 mmol) of
Ni(PPh3)2Cl2, and 4.5 mg (0.07 mmol) of Zn powder in acetonitrile.
The reaction mixture was heated at 60 °C for 20 h. The remaining
residue was purified by silica gel flash column chromatography using
15−20% ether in hexanes (Rf = 0.28 in 20% ether/hexanes) to afford
the title compound 3ac (100.8 mg, 0.30 mmol, 87%) as colorless oil.
[α]D 20 = 25.2 (c = 1.0, CHCl3); (Daicel Chiralpak OZ-H Column, 3%
i-PrOH, 25 °C, flow rate = 2 mL/min, 160 bar), Retention time:
powder in acetonitrile. The reaction mixture was heated at 80 °C for
20 h. The remaining residue was purified by silica gel flash column
chromatography using 45−55% EtOAc in hexanes (Rf = 0.25 in 55%
EtOAc/hexanes) to afford the title compound 3me (89.1 mg, 0.15
mmol, 83%) as yellow oil. [α]D 20 = −106.6 (c = 1.0, CHCl3); (Daicel
Chiralpak OZ-H Column, 5−15−50% i-PrOH, 40 °C, flow rate = 30
mL/min, 200 bar), Retention time: major = 16.82 min, minor = 17.6
min, ee = 97%].
1H NMR (400 MHz, CDCl3): δ (ppm) 7.33−7.40 (m, 5H), 6.89
(brd, J = 7.6 Hz, 1H), 6.72−6.75 (m, 2H), 6.57 (brd, J = 8.0 Hz, 1H),
6.49−6.51 (m, 2H), 5.31 (brd, J = 20.4 Hz, 1H), 5.21 (s, 2H), 4.81−
4.91 (m, 1H), 4.11−4.16 (m, 1H), 3.84 (s, 3H), 3.82 (s, 3H), 3.67 (s,
3H), 3.64 (s, 3H), 3.52 (brs, 3H), 2.40−2.55 (m, 2H), 2.20−2.27 (m,
2H). 13C NMR (100 MHz, CDCl3): δ (ppm) 194.1, 173.2, 155.4,
153.4, 149.9, 148.7, 148.5, 135.9, 133.3, 128.8, 128.6, 128.4, 126.9,
123.7, 121.7, 114.4, 112.7, 111.0, 110.7, 88.2, 68.2, 59.8, 56.0, 55.8,
52.0, 44.2, 30.8, 25.4. IR (CH2Cl2, cm−1): 2916, 2849, 1734, 1700,
1684, 1653, 1559, 1539, 1463, 1456, 1251, 1171, 1144, 1027, 764, 681.
HRMS (ESI-TOF) m/z calcd for C33H35NO9Na [M + Na]+ 612.2210,
found 612.2206.
1
minor = 4.00 min, major = 5.47 min, ee = 98%]. H NMR and 13C
NMR were consistent with reported data.5c
tert-Butyl (S)-2-Benzyl-3-oxo-4,5-dipropyl-3,6-dihydropyridine-
1(2H)-carboxylate (3ad). The general procedure G1 was used with
42.3 mg (0.16 mmol, 0.2 M) of enantiopure 2-benzyl-3-azetidinone
2d, 26.8 mg (0.24 mmol) of 4-octyne 1a, 5.3 mg (0.01 mmol) of
Ni(PPh3)2Cl2, and 2.1 mg (0.03 mmol) of Zn powder in acetonitrile.
The reaction mixture was heated at 60 °C for 20 h. The remaining
residue was purified by silica gel flash column chromatography using
10−20% ether in hexanes (Rf = 0.41 in 20% ether/hexanes) to afford
the title compound 3ad (51.2 mg, 0.14 mmol, 85%) as colorless oil.
20
[α]D = −20.7 (c = 1.0, CHCl3); (Daicel Chiralpak OZ-H Column,
3% i-PrOH, 40 °C, flow rate = 2 mL/min, 160 bar), Retention time:
1
minor = 9.99 min, major = 15.02 min, ee = 93%]. H NMR and 13C
NMR were consistent with reported data.5a,c
tert-Butyl-(S)-4,5-bis(3,4-dimethoxyphenyl)-2-(3-methoxy-3-oxo-
propyl)-3-oxo-3,6-dihydropyridine-1(2H)-carboxylate (3mf). The
general procedure G1 was used with 55.2 mg (0.22 mmol, 0.2 M)
of enantiopure 3-azetidinone 2f, 96.0 mg (0.32 mmol) of alkyne 1m,
7.0 mg (0.01 mmol) of Ni(PPh3)2Cl2, and 2.8 mg (0.04 mmol) of Zn
powder in acetonitrile. The reaction mixture was heated at 80 °C for
20 h. The remaining residue was purified by silica gel flash column
chromatography using 40−50% ethyl acetate in hexanes (Rf = 0.25 in
50% EtOAc/hexanes) to afford the title compound 3mf (105.0 mg,
Benzyl-(S)-2-(3-methoxy-3-oxopropyl)-3-oxo-4,5-dipropyl-3,6-di-
hydropyridine-1(2H)-carboxylate (3ae). The general procedure G1
was used with 53.3 mg (0.18 mmol, 0.2 M) of enantiopure 3-
azetidinone 2e, 30.2 mg (0.27 mmol) of 4-octyne 1a, 6.0 mg (0.01
mmol) of Ni(PPh3)2Cl2, and 2.4 mg (0.04 mmol) of Zn powder in
acetonitrile. The reaction mixture was heated at 60 °C for 20 h. The
remaining residue was purified by silica gel flash column chromatog-
raphy using 10−20% EtOAc in hexanes (Rf = 0.25 in 20% EtOAc/
hexanes) to afford the title compound 3ac (63.4 mg, 0.16 mmol, 86%)
as colorless oil. [α]D 20 = 13.2 (c = 1.0, CHCl3); (Daicel Chiralpak AY-
H Column, 5−15% i-PrOH, 25 °C, flow rate = 2 mL/min, 160 bar),
Retention time: major = 12.76 min, minor = 14.68 min, ee = 97%].
1H NMR (400 MHz, CDCl3): δ (ppm) 7.36 (brs, 5H), 5.13 (brs,
2H), 4.48−4.67 (m, 2H), 3.78−3.91 (m, 1H), 3.61 (s, 3H), 2.17−2.42
(m, 6H), 1.94 (m, 2H), 1.56 (m, 2H), 1.33 (sext, J = 7.6 Hz, 2H), 1.00
(m, 3H), 0.91 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ
(ppm) 194.7, 173.2, 155.1, 153.8, 136.1, 133.0, 128.8, 128.5, 128.4,
68.0, 59.5, 51.9, 43.4, 34.2, 30.8, 26.9, 25.7, 22.7, 21.8, 14.5, 14.4. IR
(CH2Cl2, cm−1): 2959, 2872, 1734, 1700, 1668, 1635, 1559, 1498,
1424, 1384, 1230, 1176, 1157, 1108, 1015, 736, 697, 668. HRMS (ESI-
TOF) m/z calcd for C23H31NO5Na [M + Na]+ 424.2100, found
424.2095.
20
0.19 mmol, 88%) as yellow gel. [α]D = −113.9 (c = 1.0, CHCl3);
(Daicel Chiralpak OZ-H Column, 5−15−50% i-PrOH, 40 °C, flow
rate = 30 mL/min, 200 bar), Retention time: major = 13.71 min,
minor = 15.17 min, ee = 95%].
1H NMR (400 MHz, CDCl3): δ (ppm) 6.87 (brm, 1H), 6.74 (d, J =
8.0 Hz, 2H), 6.59 (d, J = 8.0 Hz, 1H), 6.50 (s, 2H), 5.28 (brd, J = 20.4
Hz, 1H), 4.74 (brs, 1H), 4.05 (brd, J = 20.0 Hz, 1H), 3.84 (s, 3H),
3.83 (s, 3H), 3.70 (s, 3H), 3.67 (s, 3H), 3.53 (s, 3H), 2.50 (m, 2H),
2.18 (m, 2H), 1.52 (s, 9H). 13C NMR (100 MHz, CDCl3): δ (ppm)
194.7, 173.3, 154.5, 153.7, 149.9, 148.7, 148.5, 133.3, 129.0, 127.1,
123.8, 121.7, 114.5, 112.8, 111.0, 110.9, 110.7, 81.6, 59.9, 56.01, 56.00,
55.8, 52.0, 43.7, 39.1, 30.9, 28.6, 25.5. IR (CH2Cl2, cm−1): 2917, 2848,
1736, 1695, 1600, 1594, 1463, 1411, 1366, 1320, 1254, 1205, 1161,
764. HRMS (ESI-TOF) m/z calcd for C30H37NO9Na [M + Na]+
578.2366, found 578.2365.
ASSOCIATED CONTENT
■
S
* Supporting Information
The Supporting Information is available free of charge on the
Chromatograms of racemic and chiral dehydropiper-
idinones. 1H NMR and 13C NMR spectra of compounds
Benzyl-(S)-4,5-bis(3,4-dimethoxyphenyl)-2-(3-methoxy-3-oxo-
propyl)-3-oxo-3,6-dihydropyridine-1(2H)-carboxylate (3me). The
general procedure G1 was used with 52.7 mg (0.18 mmol, 0.2 M)
of enantiopure 3-azetidinone 2e, 81.0 mg (0.27 mmol) of alkyne 1m,
5.9 mg (0.01 mmol) of Ni(PPh3)2Cl2, and 2.4 mg (0.04 mmol) of Zn
AUTHOR INFORMATION
■
Corresponding Author
G
J. Org. Chem. XXXX, XXX, XXX−XXX